Business
TEASE-3 study: Positive interim data are reported for Stargardt drug - Ophthalmology Times Europe
Gildeuretinol halts Stargardt disease progression, study results indicate
By: Ophthalmologytimes.com
- Apr 26 2024
- 0
- 0 Views
Alkeus Pharmaceuticals Inc recently announced the interim results of the TEASE-3 study of gildeuretinol (ALK-001) which showed that treatment halted progression of early-stage Stargardt disease for u… [+8662 chars]